Privately-held Avidea is developing next-generation T cell immunotherapies for the treatment of cancer and autoimmune diseases. The company’s immunotherapies are driven by its polymer-drug conjugate technology platform, SNAPvax, which is designed to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition. This is done so in order to enable the development of immunotherapy product candidates with tighter control over immune responses. The SNAPvax platform is designed to induce high magnitude cytotoxic T cells for treating cancer and chronic infections. It can also be configured to induce regulatory T cells for treating autoimmunity and allergies.
Avidea Merger with Vaccitech Provides New Opportunities for SNAPvax Platform
